Sun Wei, Popat Uday, Hutton George, Zang Ying C Q, Krance Robert, Carrum George, Land Geoffrey A, Heslop Helen, Brenner Malcolm, Zhang Jingwu Z
Department of Neurology and Baylor Multiple Sclerosis Center, Baylor College of Medicine, Houston, Texas 77030, USA.
Brain. 2004 May;127(Pt 5):996-1008. doi: 10.1093/brain/awh117. Epub 2004 Feb 25.
Multiple sclerosis is thought to involve aberrant immune responses to myelin autoantigens. Haematopoietic stem-cell transplantation (HSCT) is in clinical trials for progressive multiple sclerosis based on the rationale that it destroys aberrant immune system, while recapitulation of lymphocyte ontogeny might alter the immune system and slow down disease progression. This study was undertaken to analyse characteristics of the T-cell receptor (TCR) repertoire, serum cytokine profile and the T-cell responses to myelin basic protein (MBP) in the reconstituted immune system in progressive multiple sclerosis. The study revealed that, following autologous HSCT, the T-cell immunity recovered in two distinctive phases. The first phase was characterized by limited T-cell immunity as a result of selective expansion of pre-existing T cells commonly expressing the TCR beta chain variable region (TCR BV) 20 and increased serum cytokine production during the first several months. The second phase of T-cell reconstitution coincided with increased thymic T-cell output 9-12 months after HSCT. T cells reconstituted from stem-cell grafts had the distinctive properties of comprehensive T-cell immunity and a broad TCR repertoire. T cells recognizing MBP were initially depleted by immunoablation and rapidly expanded from the reconstituted T-cell repertoire in 12 months. The reconstituted MBP-reactive T cells exhibited a broader epitope recognition repertoire while maintaining the same skewed reactivity pattern compared with that seen at baseline. The findings have important implications in the understanding of the role of HSCT as a potential treatment for multiple sclerosis.
多发性硬化症被认为涉及针对髓鞘自身抗原的异常免疫反应。造血干细胞移植(HSCT)正在进行针对进展性多发性硬化症的临床试验,其依据是它能破坏异常的免疫系统,同时淋巴细胞个体发生的重现可能会改变免疫系统并减缓疾病进展。本研究旨在分析进展性多发性硬化症患者经HSCT重建的免疫系统中T细胞受体(TCR)库的特征、血清细胞因子谱以及T细胞对髓鞘碱性蛋白(MBP)的反应。研究发现,自体HSCT后,T细胞免疫在两个不同阶段恢复。第一阶段的特征是T细胞免疫有限,这是由于通常表达TCRβ链可变区(TCR BV)20的预先存在的T细胞选择性扩增,以及在最初几个月血清细胞因子产生增加所致。T细胞重建的第二阶段与HSCT后9 - 12个月胸腺T细胞输出增加相吻合。从干细胞移植物重建的T细胞具有全面的T细胞免疫和广泛的TCR库的独特特性。识别MBP的T细胞最初通过免疫消融被清除,并在12个月内从重建的T细胞库中迅速扩增。与基线时相比,重建的MBP反应性T细胞在维持相同的偏斜反应模式的同时,表现出更广泛的表位识别库。这些发现对于理解HSCT作为多发性硬化症潜在治疗方法的作用具有重要意义。